Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T09:42:56.141Z Has data issue: false hasContentIssue false
  • English
  • Français

Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study

Published online by Cambridge University Press:  13 June 2014

David V. Sheehan ,
Ashok B Raj ,
K. Harnett-Sheehan ,
Sonia Soto  and
Carl P. Lewis
David V. Sheehan
Affiliation:
Professor of Psychiatry and Director of Research, Department of Psychiatry and Behavioural Medicine, University of South Florida College of Medicine, Tampa, Florida.
Ashok B Raj
Affiliation:
Associate Professor Psychiatry, Department of Psychiatry and Behavioural Medicine, University of South Florida College of Medicine, Tampa, Florida.
K. Harnett-Sheehan
Affiliation:
Assistant Professor of Psychiatry, Department of Psychiatry and Behavioural Medicine, University of South Florida College of Medicine, Tampa, Florida.
Sonia Soto
Affiliation:
Instructor of Psychiatry and Behavioural Medicine, University of South Florida College of Medicine, Tampa, Florida.
Carl P. Lewis
Affiliation:
Clinical Development, The Upjohn Company, Kalamazoo, Michigan.
Get access Rights & Permissions [Opens in a new window]

Abstract

This is the first report on the use of the sustained release formulation of adinazolam in the treatment of panic disorder. A six week open lable trial followed by a 1-6 week taper/discontinuation phase was used to assess the safety and efficacy of adinazolam (Deracyn-SR) in the treatment of 10 outpatients with panic disorder and agoraphobia. Adinazolam-SR was well tolerated and produced a rapid improvement in panic and limited symptom attacks, anxiety, phobias, disability, and depressive symptoms. Mean ±S.D. duration of therapeutic action of each dose of this formulation was 12.2±2.3 hours. This is longer than the duration of therapeutic action of other benzodiazepine formulations studied to date for the treatment of panic disorder. Frequency of relapse, rebound and withdrawal symptoms was similar to that found on taper/discontinuation from alprazolam.

Keywords

AdinazolamPanic DisorderAgoraphobiaPanic AttacksAnxietyDuration of Action.
Type
Original Papers
Information
Irish Journal of Psychological Medicine , Volume 7 , Issue 2 , September 1990 , pp. 124 - 128
Copyright
Copyright © Cambridge University Press 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Greenblatt, DJ, Shader, RI, Abernathy, DR. Current status of benzodiazepines (first of 2 parts), New Engl J Med 1983; 6: 354–358.Google Scholar
2.Herman, J. Interview in Currents in Affective Illness 1988; 7(2): 5–10.Google Scholar
3.Sheehan, DV, Coleman, JH, Greenblatt, DJ, et al.Some biological correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacology 1984; 4(2): 66–75.CrossRefGoogle ScholarPubMed
4.Pyke, RE, Cohn, JB, Feighner, JD, Smith, WT. Open label studies of adinazolam in severe depression. Psychopharmacol Bull 1986; 19: 96–98.Google Scholar
5.Feighner, JP. Controlled studies of Deracyn (adinzaolam mesylate) for major depressive episode. Abstract presented at NCDEU Annual Meeting, Key Biscayne, Florida, 1985.Google Scholar
6.Lahti, RA, Sethy, VH, Barsuhn, C, Hester, JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983; 22: 1277–82.CrossRefGoogle ScholarPubMed
7.Amsterdam, J, Kaplan, M, Potter, L, Bloom, L, Rickels, K. Adinazolam, a new triazolobenzodiazepine and imipramine in the treatment of major depressive disorder. Springer Verlag, 1986.CrossRefGoogle ScholarPubMed
8.Dunner, D, Myers, J, Khan, A, Avery, D, Pyke, R. Adinazolam, a new antidepressant: findings of a placebo-controlled double-blind study in outpatients with major depression. J. Clin Psychopharmacol 1987; 7: 170–172.Google ScholarPubMed
9.Pyke, RE, Greenberg, HS. Double blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989; 9(1): 15–21.CrossRefGoogle ScholarPubMed
10.Fleishaker, JC, Phillips, JP, Lau, HSH. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping. Biopharm Drug Disposit. 1990 (in press).Google Scholar
11.American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition revised (DSM-1II-R). Washington, D.C. 1987.Google Scholar
12.Spitzer, RL, Williams, JBW. Structured clinical interview for DSM-III-R. Biometrics Research Dept., New York State Psychiatric Institute, New York, 1987. Upjohn Version (SCID-UP-R).Google Scholar
13.Sheehan, DV. The Anxiety Disease. New York, Bantam Books (revised paperback edition), 1986.Google Scholar
14.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50.CrossRefGoogle ScholarPubMed
15.Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 1967; 6: 278–296.CrossRefGoogle ScholarPubMed
16.Derogatis, LR, Lipman, RS, Rickles, K, Uhlenhuth, EH, Covi, L. The Hopkins Symptom Checklist (HSCL): A self report symptom inventory. Behav Sci 1974; 19 (1): 1–15.CrossRefGoogle ScholarPubMed
17.Beck, AT, Ward, CH, Mendelson, M, Mock, JE, Erbaugh, JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.CrossRefGoogle ScholarPubMed
18.Winer, BJ. Statistical principles in experimental design. New York: McGraw Hill, 1971.Google Scholar
19.Pecknold, JC, Swinson, RP, Kuch, K, Lewis, CP. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, III Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–436.CrossRefGoogle ScholarPubMed